GSK To Address Multiple Myeloma With First-In-Class Blenrep In EU
Approval Conditional On Further Studies, Risk Management Plan
The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.
You may also be interested in...
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.